DHR Danaher Corporation

XNYS Up Alert

Health Care

· How we analyze

About the company

Danaher is a life sciences and diagnostics company from Washington. It makes equipment and consumables for producing biologic drugs (Cytiva), lab technology and diagnostic systems (Beckman Coulter, Cepheid). Customers are pharmaceutical companies, hospitals and labs worldwide. As of Oct 11, 2026

Fact sheet (from the annual report) Industrial measurement and control instruments · Washington, USA

Danaher groups subsidiaries from biotechnology, life sciences and diagnostics into corresponding segments. The Biotechnology segment supplies equipment, consumables, software and services for developing and manufacturing biologic drugs such as antibodies and vaccines. The Life Sciences segment offers instruments and consumables for studying genetic material, proteins and cells as well as filters for liquids and gases. The Diagnostics segment supplies hospitals and labs with instruments and tests, including molecular genetic tests. Many products and services are sold to customers on a recurring basis, mostly through direct sales. Outside the United States, its main markets are in Europe and Asia.

Automatically summarized from SEC annual report (10-K, filed Feb 24, 2026) (website of the US Securities and Exchange Commission) · reviewed Oct 14, 2026

What the methods say about Danaher

Calculated automatically by fixed rules – not investment advice, check for yourself. How we analyze

Price performance at a glance

Last 30 trading days
  • Today +1.1%
  • 7 days +3.8%
  • 30 days +3.8%
  • 1 year +4.5%
Day range (last trading day)
−1.0%Price at 71% of the range+0.4%
52-week range
−30.9%Price at 88% of the range+4.2%
Distance from the all-time high
−21.3%

Our own calculation from the exchange’s daily candles, as of Oct 26, 2026. “All-time” applies since the start of this series, not to the whole market. Changes in percent; the TradingView chart shows prices. “Today” = change of the last trading day versus the previous day. Not investment advice.

Load chart from TradingView

This transfers data (including your IP address) to TradingView, also to the USA. More in the Privacy policy.

Symbol on TradingView: NYSE:DHR

Fundamental analysis

Danaher Corporation · Sector Health Care · amounts in USD

Information only – does not affect our buy zones, not investment advice. Source: SEC filings, As of Feb 24, 2026.

In short

  • Light yellow: Revenue grew over 5 years (+2.0% per year), more slowly than the sector median.
  • Light red: Net income (total) shrank over 5 years (−0.2% per year); per share +0.6% per year.
  • Light green: Net margin 14.7%, above the sector median (12.9%).
  • Light green: Debt not higher than usual in the sector.
  • Light green: Profit in each of the last 10 fiscal years.

Summarized from the lights below. Describes the reported figures – not a recommendation to buy or sell.

RevenueNet income Net margin (below) in USD
  1. Fiscal year 2016 (Jan 1, 2016 – Dec 31, 2016): Revenue 16.9B USD · Net income 2.6B USD · Net margin 15.1%
  2. Fiscal year 2017 (Jan 1, 2017 – Dec 31, 2017): Revenue 18.3B USD · Net income 2.5B USD · Net margin 13.6%
  3. Fiscal year 2018 (Jan 1, 2018 – Dec 31, 2018): Revenue 19.9B USD · Net income 2.7B USD · Net margin 13.3%
  4. Fiscal year 2019 (Jan 1, 2019 – Dec 31, 2019): Revenue 17.9B USD · Net income 3.0B USD · Net margin 16.8%
  5. Fiscal year 2020 (Jan 1, 2020 – Dec 31, 2020): Revenue 22.3B USD · Net income 3.6B USD · Net margin 16.4%
  6. Fiscal year 2021 (Jan 1, 2021 – Dec 31, 2021): Revenue 29.5B USD · Net income 6.4B USD · Net margin 21.8%
  7. Fiscal year 2022 (Jan 1, 2022 – Dec 31, 2022): Revenue 31.5B USD · Net income 7.2B USD · Net margin 22.9%
  8. Fiscal year 2023 (Jan 1, 2023 – Dec 31, 2023): Revenue 23.9B USD · Net income 4.8B USD · Net margin 19.9%
  9. Fiscal year 2024 (Jan 1, 2024 – Dec 31, 2024): Revenue 23.9B USD · Net income 3.9B USD · Net margin 16.3%
  10. Fiscal year 2025 (Jan 1, 2025 – Dec 31, 2025): Revenue 24.6B USD · Net income 3.6B USD · Net margin 14.7%

Fiscal year 2025 (Jan 1, 2025 – Dec 31, 2025): Revenue 24.6B USD · Net income 3.6B USD · Net margin 14.7%

Key figures with traffic lights

Each light follows a simple, disclosed rule. The comparison is with the sector median of all 63 symbols in the Health Care sector on our list (current members of the S&P 500 and other lists).

Revenue growth

Light yellow: below sector

+2.0% per year, last 5 years

Sector Health Care: median +7.8% (60 symbols)

What does this mean? Revenue: over 5 years it grew by 2.0% per year on average, but more slowly than the median company in the sector (+7.8%).

Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.

Net income (total)

Light red: shrinking

−0.2% per year, last 5 years

Sector Health Care: median +7.5% (46 symbols)

per share: +0.6% per year (5 years, split-adjusted)

What does this mean? Total net income: over 5 years it fell by 0.2% per year on average. The median company in the sector reached +7.5% per year.

Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.

Net margin

Light green: above sector

14.7% last fiscal year

Sector Health Care: median 12.9% (63 symbols)

What does this mean? Of every 100 USD in revenue, 14.71 USD remained as profit – at least as much as the median company in the sector (12.9%). Five years ago the margin was 16.4%.

Light rule: Green: at least the sector median (without a sector comparison: profit) · Yellow: profit, but below the median · Red: loss.

Debt / equity

Light green: lower than sector

0.49 latest balance sheet

Sector Health Care: median 0.66 (40 symbols)

What does this mean? For every 1 USD of equity there is 0.49 USD of financial debt – no more than the median company in the sector (0.66). More debt amplifies good and bad years alike.

Light rule: Green: at most the sector median · Yellow: up to twice the median · Red: more than twice · Gray: without a sector comparison.

Payout ratio

Light gray: none found

– Dividend / earnings per share

Sector Health Care: median 28% (31 symbols)

What does this mean? The loaded SEC filings of the last two fiscal years contain no dividend per share. Either the company pays none, or it reports it under a different tag.

Light rule: Green: up to 60% of earnings · Yellow: up to 100% · Red: more than earnings or a dividend despite a loss · Gray for real estate (REITs). The sector median is for comparison only.

Profitable years

Light green: profit every year

10 of 10 fiscal years with a profit

What does this mean? In 10 of the last 10 fiscal years the bottom line showed a profit. There were no losses in this period.

Light rule: Green: profit in every year · Yellow: one loss year · Red: several loss years (at least 3 years needed).

Last fiscal year and 13F

Information, not a trading signal · Source: SEC EDGAR
Revenue (FY)
24.6B USD
Revenue vs. prior year
+2.9%
Net income (FY)
3.6B USD
Net income vs. prior year
−7.3%
EPS (FY)
5.05 USD
13F funds with a position
4 of 9
Funds vs. prior quarter
+3
Shares held vs. prior quarter
+39.0%
Fiscal year to Dec 31, 2025 · 10-K filed Feb 24, 2026 · Balance sheet Sep 25, 2026 (filed Oct 21, 2026) · Price-based figures (P/E, P/S, dividend yield, market cap) only when logged in. · Values as first reported; debt = reported financial debt (US GAAP: long-term). 13F: reporting date Jun 30, 2026, 9 tracked funds have filed (latest Aug 14, 2026), filed with up to 45 days of delay. Stock positions only; comparison with Mar 31, 2026 only across funds that filed for both quarters.
All figures as a table
Fiscal years (amounts in USD, per share in USD)
YearEndRevenueNet income MarginEarnings per shareDividend per sharePayout
2025Dec 31, 2025 24.6B3.6B 14.7% 5.05 – –
2024Dec 31, 2024 23.9B3.9B 16.3% 5.29 – –
2023Dec 31, 2023 23.9B4.8B 19.9% 6.38 – –
2022Dec 31, 2022 31.5B7.2B 22.9% 9.66 – –
2021Dec 31, 2021 29.5B6.4B 21.8% 8.61 – –
2020Dec 31, 2020 22.3B3.6B 16.4% 4.89 – –
2019Dec 31, 2019 17.9B3.0B 16.8% 4.05 – –
2018Dec 31, 2018 19.9B2.7B 13.3% 3.74 – –
2017Dec 31, 2017 18.3B2.5B 13.6% 3.53 – –
2016Dec 31, 2016 16.9B2.6B 15.1% 3.65 – –
Quarters (amounts in USD, per share in USD)
QuarterEndRevenueNet income MarginEarnings per shareDividend per sharePayout
Q3/26Sep 25, 2026 6.6B1.2B 18.8% 1.75 – –
Q2/26Jun 26, 2026 6.3B870.0M 13.9% 1.23 – –
Q1/26Mar 27, 2026 6.0B1.0B 17.3% 1.45 – –
Q4/25*Dec 31, 2025 6.8B1.2B 17.5% – – –
Q3/25Sep 26, 2025 6.1B908.0M 15.0% 1.27 – –
Q2/25Jun 27, 2025 5.9B555.0M 9.3% 0.77 – –
Q1/25Mar 28, 2025 5.7B954.0M 16.6% 1.32 – –
Q4/24*Dec 31, 2024 6.5B1.1B 16.6% – – –
Q3/24Sep 27, 2024 5.8B818.0M 14.1% 1.12 – –
Q2/24Jun 28, 2024 5.7B907.0M 15.8% 1.22 – –
Q1/24Mar 29, 2024 5.8B1.1B 18.8% 1.45 – –
Q4/23*Dec 31, 2023 6.4B1.1B 16.8% 1.45 – –

* Q4 derived: fiscal year minus the 9-month value (EPS cannot be derived this way); may be distorted by restatements.

How we calculate: values as first reported to the SEC (later corrections are left out), a fixed order of reporting tags per figure, partial sums are never added up. Growth per year over 5 years (otherwise 3 years). Quarters are labeled by the calendar quarter in which they end.

Insiders

All insider transactions
Insider purchases and sales on the market over 3, 6 and 12 months
PeriodPurchasesSalesNet
3 months $00 people $12.7M1 person −$12.7M
6 months $00 people $13.0M2 people −$13.0M
12 months $00 people $257.9M8 people −$257.9M

Latest transactions

  • Aug 21, 2026 Blair Rainer Chief executive (CEO), Director Open-market sale 7,755 shares · $1.7M · SEC
  • Aug 21, 2026 Blair Rainer Chief executive (CEO), Director Open-market sale 39,193 shares · $8.6M · SEC
  • Aug 21, 2026 Blair Rainer Chief executive (CEO), Director Open-market sale 11,307 shares · $2.5M · SEC
  • May 1, 2026 Spoon Alan G Director Open-market sale 1,358 shares · $237.2K · SEC
  • Feb 19, 2026 Milosevich Gregory M Officer Open-market sale 1,320 shares · $274.6K · SEC
  • Nov 25, 2025 Rales Mitchell P Officer, Director Open-market sale 4,726 shares · $1.1M · SEC

Source: mandatory filings with the SEC (Form 4), open-market purchases and sales only. General information, not investment advice.

Trend score +90

Price vs. EMA 50+15
Price vs. EMA 200+15
EMA 50 vs. EMA 200+20
ADX (trend strength)+15
Highs and lows+10
Relative strength+15

Volatility and trend strength

ADX 14 (trend strength)31.9
Rel. strength 60 d+17.4%

ATR and moving averages as price values only when logged in.

More stocks from Health Care

All symbols in this sector

News

Latest news

Posts

No posts on DHR yet – log in to join the discussion.

Posts are opinions of users and only visible after logging in. Community rules

Set alert: DHR

Alerts with a free account: we send you an email as soon as the price moves above or below your level, reaches the buy zone or the buy zone becomes invalid.

Checked after every data update: crypto hourly (buy zones every 4 hours), stocks twice a day, precious metals every 4 hours on trading days, extended universe weekly – not in real time.

Log in Sign up free

↑ ↓ select · Enter open · Esc close